康芝药业
(300086)
| 流通市值：20.93亿 | | | 总市值：21.62亿 |
| 流通股本：4.41亿 | | | 总股本：4.55亿 |
| 利润表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 营业总收入 | 195,849,316.05 | 144,887,847.09 | 96,573,833.91 | 466,122,703.87 |
| 营业总成本 | 280,153,239.97 | 184,674,015.53 | 105,357,588.5 | 650,931,951.28 |
| 其他经营收益 | | | | |
| 营业利润 | -72,579,916.52 | -27,654,332.95 | -6,462,492.15 | -257,307,939.33 |
| 利润总额 | -72,390,992.48 | -27,649,025.15 | -6,387,974.8 | -259,472,149.65 |
| 净利润 | -76,937,179.78 | -33,533,982.51 | -12,139,036.55 | -234,028,867.48 |
| 每股收益 | | | | |
| 其他综合收益 | - | - | - | 14,335,824.51 |
| 综合收益总额 | -76,937,179.78 | -33,533,982.51 | -12,139,036.55 | -219,693,042.97 |
| 资产负债表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 流动资产: | | | | |
| 流动资产合计 | 220,063,004.89 | 258,314,688.45 | 268,806,788.96 | 304,478,619.13 |
| 非流动资产: | | | | |
| 非流动资产合计 | 1,447,022,427.55 | 1,453,331,710.22 | 1,468,423,995.3 | 1,486,526,147.35 |
| 资产总计 | 1,667,085,432.44 | 1,711,646,398.67 | 1,737,230,784.26 | 1,791,004,766.48 |
| 流动负债: | | | | |
| 流动负债合计 | 566,632,602.07 | 567,168,897.03 | 542,487,879.51 | 583,491,864.39 |
| 非流动负债: | | | | |
| 非流动负债合计 | 256,216,688 | 256,828,488.5 | 285,685,289.01 | 286,297,087.7 |
| 负债合计 | 822,849,290.07 | 823,997,385.53 | 828,173,168.52 | 869,788,952.09 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 823,875,799.26 | 866,910,179.75 | 887,940,580.06 | 899,709,487.23 |
| 股东权益合计 | 844,236,142.37 | 887,649,013.14 | 909,057,615.74 | 921,215,814.39 |
| 负债和股东权益合计 | 1,667,085,432.44 | 1,711,646,398.67 | 1,737,230,784.26 | 1,791,004,766.48 |
| 现金流量表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 258,267,894.84 | 195,570,119.65 | 112,892,773.59 | 728,183,776.89 |
| 经营活动现金流出小计 | 295,569,912.42 | 206,813,379.46 | 135,822,302.81 | 606,941,712.51 |
| 经营活动产生的现金流量净额 | -37,302,017.58 | -11,243,259.81 | -22,929,529.22 | 121,242,064.38 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 460 | 460 | 460 | 84,366.68 |
| 投资活动现金流出小计 | 6,946,335.78 | 5,022,217.34 | 3,891,509.94 | 92,172,653.35 |
| 投资活动产生的现金流量净额 | -6,945,875.78 | -5,021,757.34 | -3,891,049.94 | -92,088,286.67 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 211,345,585.69 | 56,371,088 | 10,091,307 | 252,925,908.4 |
| 筹资活动现金流出小计 | 221,024,219.68 | 83,469,516.67 | 25,728,760.15 | 330,851,623 |
| 筹资活动产生的现金流量净额 | -9,678,633.99 | -27,098,428.67 | -15,637,453.15 | -77,925,714.6 |
| 汇率变动对现金及现金等价物的影响 | -54,414.22 | -42,025.27 | -24,534.99 | -22,596.7 |
| 现金及现金等价物净增加额 | -53,980,941.57 | -43,405,471.09 | -42,482,567.3 | -48,794,533.59 |
| 期末现金及现金等价物余额 | 5,771,004.69 | 16,346,475.17 | 17,269,378.96 | 59,382,790.81 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | - | -43,405,471.09 | - | -48,794,533.59 |